Ablation of sphingosine kinase 2 suppresses fatty liver-associated hepatocellular carcinoma via downregulation of ceramide transfer protein

Xin Tracy Liu1,6, Long Hoa Chung1,6, Da Liu1, Jinhiao Chen1, Yu Huang1, Jonathan D. Teo2, Xingxing Daisy Han1, Yinan Zhao3, Fiona H. X. Guan4, Collin Tran2, Jun Yup Lee2, Timothy A. Couttas5, Ken Liu4, Geoffrey W. McCaughan4,1,4, Mark D. Gorrell3,1,4, Anthony S. Don2,3,5, Shubiao Zhang3,15 and Yanfei Qi13

© The Author(s) 2022

Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancer, the third leading cause of cancer-associated death worldwide. With the increasing prevalence of metabolic conditions, non-alcoholic fatty liver disease (NAFLD) is emerging as the fastest-growing HCC risk factor, and it imposes an additional layer of difficulty in HCC management. Dysregulated hepatic lipids are generally believed to constitute a deleterious environment cultivating the development of NAFLD-associated HCC. However, exactly which lipids or lipid regulators drive this process remains elusive. We report herein that sphingosine kinase 2 (SphK2), a key sphingolipid metabolic enzyme, plays a critical role in NAFLD-associated HCC. Ablation of Sphk2 suppressed HCC development in NAFLD livers via inhibition of hepatocyte proliferation both in vivo and in vitro. Mechanistically, SphK2 deficiency led to downregulation of ceramide transfer protein (CERT) that, in turn, decreased the ratio of pro-cancer sphingomyelin (SM) to anti-cancer ceramide. Overexpression of CERT restored hepatocyte proliferation, colony growth and cell cycle progression. In conclusion, the current study demonstrates that SphK2 is an essential lipid regulator in NAFLD-associated HCC, providing experimental evidence to support clinical trials of Sphk2 inhibitors as systemic therapies against HCC.

Oncogenesis (2022)11:67; https://doi.org/10.1038/s41389-022-00444-0

INTRODUCTION

Primary liver cancer was estimated to result in 8.3% of all cancer-related deaths worldwide in 2020, making it the third leading cause following lung and colorectal cancer [1]. Hepatocellular carcinoma (HCC) accounts for >90% of primary liver cancer [2]. In recent years, non-alcoholic fatty liver disease (NAFLD) is emerging as the fastest-growing etiology of HCC in developed countries [2]. In HCC of all causes, cirrhosis is the most prevalent pathological event [3]. However, approximately 40% of NAFLD-associated HCC (NAFLD-HCC) can develop from non-cirrhotic livers [4], suggesting that NAFLD-HCC may represent a unique pathogenic route. In NAFLD-HCC, hepatic lipid dysregulation is believed to constitute a deleterious environment that cultivates cancer initiation and progression. However, the lipid risk factors in this condition have not yet been adequately explored [5]. So far, the management of HCC remains challenging. NAFLD creates an additional layer of difficulty in the systemic treatment [6], and, worse still, there is no FDA-approved drug for NAFLD [7]. As such, understanding the lipid metabolic causes of NAFLD-HCC is a fundamental step in developing effective treatment and a key topic in liver cancer research.

Sphingolipids are essential lipids that act as cell membrane constituents and signaling molecules [8] and have been implicated in cancer development [9, 10]. Ceramide is the central metabolite in the sphingolipid metabolic network [8–10]. Once synthesized in the endoplasmic reticulum, the majority of ceramide serves as the substrate for the synthesis of more complex sphingolipids, mainly sphingomyelin (SM) [11]. In the ceramide-to-SM conversion, ceramide is delivered to the trans-Golgi by its unique intracellular transporter, ceramide transfer protein (CERT) [12], which enables its access to sphingomyelin synthase 1 and 2 (SMS1 and SMS2) for SM production [13, 14]. SM is subsequently distributed to the plasma membrane or other subcellular membrane compartments [15], where it can be hydrolyzed back to ceramide by neutral sphingomyelinase (nSMase) or acid SMase (aSMase) [16, 17]. The balance between SM and ceramide is a critical determinant of cell fate. SM is considered a pro-cancer factor, promoting cell survival, proliferation, and migration [14, 18–20], and it is increased in human HCC compared with para-tumorous tissues [21–23]. In contrast, ceramide has been well characterized as an anti-cancer factor, inducing apoptosis and cell cycle arrest [10, 24], and it is
decreased in human HCC compared with adjacent non-tumorous tissues [21–23]. Therefore, efforts to understand and modulate SM/ceramide homeostasis may provide a new approach to HCC management. Sphingolipid levels are determined by their catabolism, where sphingosine kinase (SphK) is the rate-limiting enzyme [8]. In brief, ceramide is hydrolyzed into sphingosine and a free fatty acid (FFA), followed by SphK-mediated phosphorylation of sphingosine to form sphingosine 1-phosphate (S1P), and then hydrolysis of S1P into non-sphingolipid products [8, 9]. There are two mammalian isoforms of SphK, denoted SphK1 and SphK2. SphK2 is the predominant isoform in the liver, contributing to 90% of total SphK activity [25]. Only a few studies have investigated the role of SphK2 in HCC. Administration of the selective SphK2 inhibitor ABC294640 profoundly suppresses the growth of HepG2 or SK-HEP-1 HCC xenografts [26]. Knockdown or inhibition of SphK2 sensitizes HCC cells to the chemotherapeutic agent regorafenib in vitro [27]. These all suggest a pro-cancer role of SphK2 in HCC. In addition, ABC294640 has been tested for HCC treatment in a Phase I clinical trial (ClinicalTrials.gov Identifier: NCT01488513), was planned to be used as a monotherapy for advanced HCC in a Phase II study (NCT02939807), and is being tested for intrahepatic cholangiocarcinoma (NCT03377179). Surprisingly, SphK2 has never been studied in any primary liver cancer models in vivo. Furthermore, we and others have identified SphK2 as a critical regulator of NAFLD and hepatic insulin resistance in diet-induced obese mice [28, 29]. Therefore, investigating the role of SphK2 in the development of NAFLD-HCC is important.

In this study, we examined the role of SphK2 in NAFLD-HCC using Sphk2 knockout (KO) mice on a high-fat, high-sugar diet (HFD). In addition to liver tumor incidence, we examined immune cell infiltration, fibrosis, and cell proliferation in mouse livers upon ablation of Sphk2. We also assessed the anti-cancer effects of SphK2 deficiency on cell viability, clonogenicity and cell cycle in hepatic cells exposed to a high-fat environment. Through a near complete profiling of the lipidome in mouse livers, we identified that deletion of Sphk2 disrupted the balance between SM and ceramide via downregulation of CERT. We also visualized SM and ceramide levels in human HCC specimens using mass spectrometry imaging. We further showed that downregulation of CERT was responsible for the tumor-suppressive effects of SphK2 deficiency. Collectively, our study revealed a previously unknown link between Sphk2 and CERT in sphingolipid homeostasis and a critical role of Sphk2 in NAFLD-HCC.

RESULTS

Ablation of Sphk2 suppresses HCC development in diet-induced obese mice

The Cancer Genome Atlas (TCGA) data analyses showed that the hepatic Sphk2 level was significantly increased in HCC as compared with normal livers, and it was further increased in extremely obese HCC patients (Suppl Fig. 1). This suggests an association of SphK2 with NAFLD-HCC, as NAFLD is highly prevalent in obese subjects [30]. To examine the role of Sphk2 in the development of NAFLD-HCC, we fed wild-type (WT) and Sphk2-KO mice an HFD for 46 weeks in the absence of any chemical carcinogens. Sphk2-KO mice exhibited significantly lower body weight gain than their WT littermates (Fig. 1A, B). The liver mass and epididymal white adipose tissue (eWAT) mass were also lower in Sphk2-KO mice (Fig. 1C, E). However, the percentages of liver mass and eWAT mass to body weight were indistinguishable between the two genotypes (Fig. 1D, F). The levels of plasma non-esterified fatty acid (NEFA), total cholesterol (TC) and triglyceride (TG) were decreased in Sphk2-KO mice (Fig. 1G–I). Visible liver tumors developed in 3 of 14 WT mice, and neoplastic lesions were found in the liver of an additional 2 WT mice by microscopic examination (Fig. 1J–L). In contrast, neither visible tumors nor neoplastic lesions were identified in the equivalent number of Sphk2-KO mice (Fig. 1J–L).

Ablation of Sphk2 mitigates HCC-promoting pathological changes in non-tumorous liver tissues

Extensive efforts have been made to elucidate cellular and histological disparities between tumorous and non-tumorous tissue in HCC, but the microenvironmental factors that determine HCC outcomes in non-tumorous tissues are understudied. In the following work, we mainly focused on analyzing the differences in non-tumorous liver tissues of WT and Sphk2-KO mice in order to understand why Sphk2-KO suppressed NAFLD-HCC. Comparable levels of steatosis were found in the parenchyma of WT and Sphk2-KO livers using hematoxylin and eosin (H&E) staining (Fig. 2A, B). However, Sphk2-KO significantly ameliorated immune cell infiltration, hepatocyte ballooning, NAFLD activity score (NAS) and hepatic fibrosis in non-tumorous tissues (Fig. 2C–F), which are classic hallmarks of pro-carcinogenic injury in NAFLD-HCC. In line with this, plasma alanine aminotransferase (ALT) activity was reduced by 66% in Sphk2-KO mice (Fig. 2G). In addition, the percentage of cells positive for proliferation marker Ki67 was decreased by 3.4-fold in Sphk2-KO livers (Fig. 2H), suggesting that Sphk2 deficiency might exhibit anti-NAFLD-HCC effects at the cellular level.

Anti-cancer effects of SphK2 deficiency in FFA-treated hepatic cells

We next examined whether Sphk2 deficiency led to anti-cancer effects in hepatocytes. To simulate a high-fat environment in vitro, we treated Huh7 cells with a combination of palmitate and oleate. As expected, viable cell number doubled approximately every 24 h in the control group (shCtrl) over the three days of FFA treatment, whereas cell proliferation was impaired by shRNA-mediated knockdown of Sphk2 (shSphk2, Fig. 3A). In the absence of FFA treatment, viable cell number increased at a lower rate, and Sphk2 knockdown had minimal effects on cell proliferation (Suppl Fig. 2). Subsequently, we examined the clonogenicity of FFA-treated cells. The colony number was comparable between control and Sphk2 knockdown cells, whereas colony size was decreased by 78–84% in Sphk2 knockdown cells (Fig. 3B). This result also implies an anti-proliferative effect of Sphk2 deficiency in a high-fat environment. To further this notion, we analyzed the cell cycle using flow cytometry. Knockdown of Sphk2 significantly suppressed cell cycle progression to the G2/M phase (Fig. 3C).

Ablation of Sphk2 alters the balance between SM and ceramide in mouse livers

To explicate the lipid metabolic basis underlying the anti-NAFLD-HCC effects of Sphk2-KO, we examined lipid changes in non-tumorous liver tissues using lipidomics. First, we determined 12 major FFAs. The hepatic levels of oleic acid and palmitic acid, the two most abundant FFA species, were significantly decreased in Sphk2-KO mice (Suppl Fig. 3A). Levels of cholesterol ester (CE), diglyceride (DG), TG, phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylserine (PS), and phosphatidylinositol (PI) and phosphatidylserine (PS) were unaltered in Sphk2-KO livers (Suppl Fig. 3B–D). The hepatic content of neutral lipids, including CE and TG, confirmed that mice of the two genotypes developed a similar degree of hepatic steatosis (Fig. 2B). Ablation of Sphk2 resulted in a slight elevation of free cholesterol (FC) levels in the liver (Suppl Fig. 3B). In contrast, FC levels were significantly decreased in Sphk2-KO knockdown hepatic cells, without prominent alterations in its subcellular localization (Suppl Fig. 4A, B). Since Sphk2 is key to sphingolipid catabolism, we next focused on sphingolipids. Dihydro-sphingosine, dihydro-ceramide, ceramide, and sphingosine sit proximally upstream of Sphk2-mediated sphingolipid catabolism [8]. When Sphk2 was
ablated, the three most abundant hepatic dihydro-ceramide and ceramide species (C16:0, C22:0, and C24:1), as well as dihydro-
sphingosine and sphingosine, were significantly increased (Fig.
4A–C and Suppl Fig. 3E). In contrast, hepatic levels of S1P and
dihydro-S1P, the products of SphK2, were unchanged in these
unperfused liver tissues (Fig. 4D and Suppl Fig. 3F). In the
sphingolipid metabolic network, complex sphingolipids are distal
to SphK2-mediated regulation. They are normally highly abundant
and cannot be altered by SphK2 manipulation. Indeed, hexosyl-
ceramide (HexCer) levels were unchanged (Suppl Fig. 3G).
However, unexpected results were seen at SM levels. Remarkably
opposed to ceramide and dh-ceramide, C16:0, C22:0, and C24:1
SM were significantly decreased in Sphk2-KO livers deficiency (Fig.
4E), resulting in a 64% reduction in the ratio of SM to ceramide (Fig.
4F). We also examined ceramide and SM levels in FFA-treated Huh7 cells.
Consistent with the in vivo findings, knockdown of Sphk2
increased ceramide and decreased SM levels, leading to a
significant 55% reduction in the ratio of SM to ceramide (Fig.
4G–I). To further test the notion that SM/ceramide ratio is
associated with HCC development, we examined the levels of
C24:1 SM and C24:1 ceramide, the most abundant hepatic SM and
ceramide species in human HCC and para-tumorous tissues, using
mass spectrometry imaging. We found that C24:1 SM levels were
increased, whereas C24:1 ceramide levels were decreased, in the
tumorous tissues as compared with para-tumorous tissues (Fig.
4J). Notably, the SM/cer ratios were increased in the tumorous
tissues of all specimens (Fig. 4J).

Deletion of Sphk2 results in downregulation of CERT
Given the importance of SM/ceramide ratio in HCC, we next
investigated the cause of SM/ceramide ratio change upon Sphk2
deficiency. To this end, we examined key factors that primarily

Fig. 1 Sphk2-KO suppresses liver cancer development in HFHSD-fed mice. Wild-type (WT) and Sphk2 knockout (KO) mice were fed with a
high-fat, high-sugar diet (HFHSD) for 46 weeks. A body weight (BW) gain, B Photos of WT and KO littersmates showing different BW gain, C liver
mass, D % of liver mass/BW, E epididymal white adipose tissue (eWAT) mass, F % of eWAT/BW, G plasma non-esterified fatty acids (NEFA),
H plasma total cholesterol (TC) and I plasma triglyceride (TG). J Tumor incidence. 3 of 14 WT developed visible tumors and an additional 2 of
14 WT mice developed neoplastic lesions in the liver, while 0 of 14 KO mice developed neither liver tumors nor lesions. K Macroscopic images
of visible liver tumor. L Microscopic images of the neoplastic lesion following H&E staining, scale bar = 200 µm. Data are expressed as
mean ± SD. n = 14. *p < 0.05; **p < 0.01; ***p < 0.001; versus WT.
regulated the interconversion between ceramide and SM in the livers of HFHSD-fed mice. These factors include CERT, SMS1, aSMase, and nSMase. Ablation of Sphk2 led to a downregulation of CERT protein, while SMS1, aSMase and nSMase levels were unaltered (Fig. 5A). In line with this, Cert1 mRNA was significantly decreased in Sphk2-KO livers (Fig. 5B). These findings were confirmed in FFA-treated Huh7 cells, in which knockdown of Sphk2 resulted in a downregulation of CERT protein and mRNA (Fig. 5C, D), suggesting that Sphk2 regulated CERT expression at the transcriptional level. Nuclear factor-κB (NF-κB) is a primary transcription factor of CERT [31], and thus we examined the activation of NF-κB by determining the phosphorylation of its p65 subunit. Knockdown of Sphk2 greatly reduced p65 phosphorylation in FFA-treated cells (Fig. 5E), associated with the decrease of CERT protein and mRNA levels (Fig. 5C, D). In contrast, p-p65 levels were relatively low, and shSphk2 marginally repressed p65 phosphorylation, in the absence of FFA loading (Suppl Fig. 5B). In accord, shSphk2 did not alter CERT protein and mRNA expression when no FFA was added (Fig. 5D and Suppl Fig. 5A, B). We further analyzed the correlation between SPHK2 and CERT1 genes in the human HCC dataset sourced from TCGA, focusing on NAFLD-HCC. Due to the lack of NAFLD diagnostic information, we extracted data from human subjects with body mass index (BMI) > 25 in the TCGA-LIHC dataset, as BMI is strongly associated with NAFLD risk [30]. We found that SPHK2 and CERT1 mRNA levels were positively correlated in overweight or obese HCC subjects (Fig. 5F).

**Discussion**

The anti-cancer effects of Sphk2 deficiency have been demonstrated in HCC cell lines and xenograft models [26, 27]. However, the in vivo role of Sphk2 was never studied in any primary HCC models, which restricts the development of new anti-HCC therapies.
treatments targeting SphK2. To define the exact role of SphK2 in NAFLD-related HCC in vivo, we fed Sphk2-KO mice an HFHSD to induce liver tumors. The HFHSD model recapitulates the development of spontaneous HCC in NAFLD livers and enables a focus on the underlying lipid metabolic causes. Long-term exposure to an HFHSD leads to liver tumors in mice with varied incidence rates up to 68.8% [32–35]. We identified visible liver tumors and neoplastic lesions in 35.7% of WT mice (Fig. 1J). In marked contrast, no tumors or lesions were found in Sphk2-KO mice (Fig. 1J), defining a requirement for SphK2 in NAFLD-HCC development in vivo. Microenvironmental changes and pro-cancer cellular alterations contribute synergistically to HCC development [36]. SphK2 deficiency abrogated HFHSD-induced body weight gain, hyperlipidemia, hepatic inflammation and fibrosis (Figs. 1 and 2), resulting in a tumor-suppressive microenvironment. Meanwhile, Sphk2 deficiency inhibited hepatocyte proliferation under a high-fat condition both in vivo and in vitro (Figs. 2H and 3), which demonstrates another layer of its anti-NAFLD-HCC effects at the cellular level. In line with this, we and others have found that ablation of SphK2 impairs, whereas overexpression of SphK2 activates the signaling of Akt, a master regulator of cell proliferation [28, 29, 37]. Our results collectively indicate that SphK2 deficiency reduces HCC risk in fatty livers at both systemic and cellular levels, providing in vivo experimental evidence for clinical trials of SphK2 inhibitors as systemic therapies against NAFLD-HCC. The anti-HCC effects of SphK2 deficiency warrant further examination in more complex primary HCC mouse models, including HFHSD combined with DEN or fibrogenic agents. In addition, the hepatocyte-autonomous roles of SphK2 in HCC development should be further elucidated using cell type-specific knockout mice.

Dysregulated lipids are believed to drive NAFLD progression to HCC, but exactly which hepatic lipids impose significant HCC risk remains elusive [5]. We found that both WT and Sphk2-KO mice developed a similar level of hepatic steatosis upon HFHSD feeding, as reflected in H&E staining (Fig. 2A, B) and hepatic TG and CE determination (Suppl Figs. 3B and 3C). This supports the notion that accumulation of neutral lipids in the liver represents the degree of simple hepatosteatosis but not the risk for carcinogenic injury [38]. In contrast, increased FC in hepatocytes promotes cytotoxicity and proinflammatory responses, predisposing to the development of NASH and HCC [39–43]. Correspondingly, dietary cholesterol reprograms genetic and metabolic signatures in the liver, in favour of NASH-HCC [44]. Adenoviral overexpression of SphK2 significantly reduces total hepatic cholesterol (FC + CE) in HFD-fed mice [29]. Consistently, Sphk2-KO mice exhibited slightly elevated hepatic FC levels, with unchanged CE levels (Suppl Fig. 3B). Sphk2-KO profoundly downregulates gene expression of many key regulators in hepatic cholesterol homeostasis, including low-density lipoprotein.

Fig. 3 The anti-cancer properties of SphK2 deficiency in FFA-treated hepatic cells. Huh7 hepatic cells were transduced with lentiviral-based short hairpin RNA (shRNA) to knock down Sphk2 and then treated with a combination of free fatty acids (FFA, 200 µM palmitate + 400 µM oleate). A Cell viability was determined by MTS assay in cells treated with FFA for the indicated times; n = 4. B Colony formation assay was performed over ten days of cell culture in the presence of FFA. The number and size of colonies were quantified; n = 5. C Cell cycle phases were examined in cells treated with FFA for 24 h, using flow cytometry with propidium iodide staining. G0/G1, S, and G2/M phase populations were estimated using FlowJo software and are indicated in blue, yellow and green in histograms, respectively. The percentage of the G2/M phase, indicative of cell cycle progression, was analyzed, n = 5. Data are expressed as mean ± SD. *p < 0.05; **p < 0.001; versus shCtrl.
Fig. 4  The altered sphingolipid profile in Sphk2-KO livers. A–F Wild-type (WT) and Sphk2 knockout (KO) mice were fed with a high-fat, high-sugar diet (HFHSD) for 46 weeks. G–I Huh7 hepatic cells were transduced with lentiviral-based short hairpin RNA (shRNA) to knock down SphK2 and then treated with a combination of free fatty acids (FFA, 200 µM palmitate + 400 µM oleate) for 48 h. Lipids were extracted in non-tumorous liver tissues and FFA-treated cells and analyzed using lipidomics. (A) dihydro-ceramide (dhCer), B, G ceramide (Cer), C sphingosine (Sph), D sphingosine 1-phosphate (S1P), and E, H sphingomyelin (SM) were determined. F, I the ratio of SM to ceramide. J Levels of C24:1 SM and C24:1 Cer in human HCC (T) and adjacent non-tumorous (NT) tissues were visualized and using DESI mass spectrometry imaging coupled with ion mobility and quantified by HDI software. Data are expressed as mean ± SD. n = 8 A–F; n = 4 G–I; n = 5 J. *p < 0.05; **p < 0.01; ***p < 0.001, versus control.
receptor, sterol 27-hydroxylase, farnesoid X receptor α and bile salt export pump [45]. This might lead to hepatic cholesterol disturbance with long-term HFD feeding. Contrasting with the FC changes in vivo, SphK2 deficiency decreased FC levels in hepatic cells in vitro (Suppl Fig. 4A), implicating SphK2 in non-hepatocyte-autonomous regulation of hepatic cholesterol homeostasis in vivo. Given the importance of FC in non-alcoholic steatohepatitis (NASH) and HCC, the role of SphK2 in hepatic cholesterol homeostasis should be investigated in further studies. In the present work, this minor hepatic FC increase was not sufficient to overwhelm the tumor-suppressive effects of Sphk2-KO. In addition, SphK2 did not alter the hepatic levels of phospholipids (Suppl Fig. 3D). Therefore, it was unlikely that SphK2 regulated HCC development via cholesterol or phospholipid metabolism in the

Fig. 5  SphK2 deficiency downregulates CERT both in vivo and in vitro. A, B Wild-type (WT) and Sphk2 knockout (KO) mice were fed with a high-fat, high-sugar diet (HFHSD) for 46 weeks. A Proteins were extracted from non-tumorous liver tissues and analyzed using Western blotting. Expression levels of the indicated proteins were quantified; n = 8. B mRNA expression of Cert1, the gene encoding mouse CERT, was examined by real-time RT-PCR; n = 8. C–E HuH7 hepatic cells were transduced with lentiviral-based short hairpin RNA (shRNA) to knock down SphK2 and then treated with a combination of free fatty acids (FFA, 200 µM palmitate + 400 µM oleate) for 48 h. C, E Proteins were extracted from cells and analyzed using Western blotting. The CERT protein expression and phospho-p65 over total p65 (p-p65/t-p65) were quantified; n = 5. D mRNA expression of CERT1, the gene encoding human CERT, was examined in the presence and absence of the FFA treatment by real-time RT-PCR; n = 4. A–E Data are expressed as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; versus control. F The correlation of SPHK2 and CERT1 mRNA expression was analyzed in human HCC subjects with body mass index > 25. Data are sourced from TCGA (https://portal.gdc.cancer.gov).
liver. Accumulation of palmitic acid, the most abundant saturated FFA, in the liver can induce NASH characterized by hepatic fibrosis and inflammation, leading to HCC [46, 47]. In addition, the accumulation of oleic acid, the most abundant mono-unsaturated FFA, in the liver also contributes to HCC development by promoting hepatic cell proliferation [48]. Consistent with its HCC-suppressive phenotype, Sphk2-KO decreased hepatic levels of both palmitic acid and oleic acid (Suppl Fig. 3A). The decrease of hepatic FFA might result from the reduction of circulating NEFA in Sphk2-KO mice (Fig. 1G), as the latter is the primary source of the former in human fatty liver disease [49]. The regulation of hepatic FFA levels might, at least in part, explain the anti-NAFLD-HCC effects of Sphk2-KO.

It was expected that ablation of Sphk2 would cause significant sphingolipid remodelling. Indeed, dihydro-ceramide, ceramide, dihydro-sphingosine and sphingosine were increased in Sphk2-KO livers (Fig. 4A–C and Suppl Fig. 3E), as all of them reside upstream of Sphk2-mediated enzymatic regulation in the sphingolipid metabolic network [8]. However, S1P, the catalytic product of Sphk2, was only marginally decreased in Sphk2-KO livers (Fig. 4D). This could be due to the presence of blood in the tissue samples. S1P levels are much higher in blood than in tissues, due to the lack of S1P-degrading enzymes, S1P lyase and S1P phosphohydrolase, in erythrocytes [50]. Any blood contamination in isolated tissues would cause inaccurate quantitation of S1P [51]. This is more problematic in Sphk2-KO mice. Sphk2 is essential for the disposal of blood S1P in the liver, and thus ablation of Sphk2 ordinarily elevates blood S1P levels by 2-3 fold [51, 52]. We did not perfuse mice prior to the isolation of the liver tissues for this study, as it was important to examine the immune cell infiltration. Therefore, it is not surprising that S1P levels were only marginally reduced in unperfused Sphk2-KO livers (Fig. 4D). In support of this, we have previously demonstrated that S1P levels are significantly decreased in both Sphk2 global KO and hepatocyte-specific KO (LKO) mouse livers after perfusion [28, 53]. SphK1 redundancy after Sphk2 deletion might also contribute to the maintenance of hepatic S1P levels. However, SphK1 is expressed at low levels [29] and only accounts for ~10% of total SphK activity [25] in the liver. We found no changes in Sphk1 levels after Sphk2 knockout (Fig. 5A). Although the unchanged protein expression cannot preclude possible redundancy in enzymatic activity, this data suggests that Sphk1 redundancy, if present, would be minor.

SM represents the most abundant sphingolipid subclass [13]. It is also an essential structural lipid in cellular membranes,
particularly lipid rafts [54], where it promotes cell proliferation and growth [14, 19, 55, 56]. In marked contrast, ceramide is known as a tumor-suppressive factor in most cancer types via a variety of biological actions, including the inhibition of cancer cell proliferation [10, 24]. Consistently, we found that SM levels were increased, whereas ceramide was decreased in human HCC tissues, as compared with the para-tumorous tissue (Fig. 4J). C6-ceramide decreased cell viability (Suppl Fig. 6A), confirming the cytotoxic effects of this compound. However, the reduction of cell viability was comparable between control and SphK2 knockdown cells, indicating that increased ceramide alone could not explain the inhibition of cell proliferation induced by SphK2 deficiency (Suppl Fig. 6A). We also decreased endogenous ceramide levels by treatment with the ceramide synthase inhibitor fumonisin b1. If increased ceramide was a leading cause for the defects upon SphK2 deficiency, fumonisin b1 should restore cell proliferation in SphK2 knockdown cells. However, fumonisin b1 induced an additional decrease in cell viability by up to 15% in shSphK2 cells as compared with shCtrl cells (Suppl Fig. 6B). These data together suggest that increased ceramide was not the sole factor in SphK2 deficiency-mediated regulation. Instead, mounting evidence has demonstrated that the ratio of SM/ceramide might determine the outcome of cancer development [57]. In line with this notion, SphK2 deficiency differentially regulated ceramide and SM levels in HFFHSD-fed mouse livers and FFA-treated Huh7 hepatic cells, leading to a profound decrease in SM/ceramide ratio (Fig. 4F, I), which was associated with its anti-HCC phenotype (Fig. 1).

The ratio of SM/ceramide is dictated by three key regulators: CERT, SMS, and SMases, and the key step in ceramide-to-SM conversion is ceramide transport from the endoplasmic reticulum to the trans-Golgi, mediated by CERT [12]. It is well demonstrated that CERT can determine the ratio of SM/ceramide, independent of SMS and SMases [12, 58–61]. Sphk2-KO resulted in a significant downregulation of CERT but did not alter levels of SM51, aSMase, and nSMase in the liver tissues, indicating that the change of CERT accounted for the decreased ratio of SM/ceramide (Fig. 5A, B). This was also observed in hepatic cells treated with FFAs (Fig. 5C, D). SphK2 deficiency decreased CERT mRNA levels both in vivo and in vitro (Fig. 5B, D), indicative of transcriptional regulation. It has been demonstrated that CERT gene transcription is regulated by NF-κB, and thus tumor necrosis factor α can increase CERT mRNA levels by 3-4 fold via NF-κB activation [31]. Sphk2 knockdown profoundly suppressed NF-κB activation in cells loaded with FFA (Fig. 5E). This might contribute to the downregulation of CERT. In support of this, both knockdown and inhibition of SphK2 inhibit NF-κB activation in regorafenib-resistant HCC cells [27]. Exactly how SphK2 regulates NF-κB activation and whether other transcription factors are implicated in the regulation of CERT levels are worthy of further investigation.

Multiple lines of evidence have demonstrated that CERT is highly expressed in drug-resistant human subjects with ovarian and breast cancers [60, 62, 63]. In addition, knockdown of CERT sensitizes HCT-116 human colon cancer cells, BT474, HCC1954 and SK-BR3 HER2 + breast cancer cell lines, MDA-MB-231 human triple-negative breast cancer cells and A549 human lung carcinoma cells to apoptosis induced by chemotherapy agents [60, 62]. Furthermore, knockdown or inhibition of CERT leads to cell cycle arrest in murine embryonic cells and paclitaxel-treated HCT-116 cells [60, 62, 64]. To examine if CERT downregulation was critical for the anti-HCC effects of SphK2 deficiency, we overexpressed CERT in control and SphK2 knockdown hepatic cells. We found that overexpression of CERT restored cell proliferation, colony formation, and cell cycle progression in SphK2-deficient hepatic cells (Fig. 6). Notably, SphK2-mediated regulation of CERT is dependent on a high-fat environment. Knockdown of SphK2 failed to downregulate CERT levels or suppress hepatic cell proliferation in the absence of FFA treatment (Fig. 5D, Suppl Figs. 2, 5A, B). The different effects of SphK2 knockdown on CERT expression and cell proliferation between untreated and FFA-treated hepatic cells might be attributed to the states of NF-κB activation (Suppl Fig. 5B). FFA treatment dramatically activated NF-κB, which was suppressed by SphK2 deficiency (Suppl Fig. 5B). In contrast, the active form of NF-κB (p-p65) stayed at a relatively low level in untreated cells (Suppl Fig. 5B). In accord, CERT protein levels were regulated in the same fashion (Suppl Fig. 5B). Similarly, NF-κB is activated in drug-resistant cancer cells [27], and CERT is highly expressed in drug-resistant human cancers [60, 62, 63]; whereas, a lower CERT expression level is reported in some human cancers in the absence of chemotherapies [59, 65, 66]. These studies suggest that CERT may play a more explicit pro-cancer role under stress, such as chemotherapies and overnutrition, when the conversion of pro-apoptotic/anti-proliferative ceramide to proliferative SM is more critical for cell proliferation and growth.

In summary, the current study provides both in vivo and in vitro evidence demonstrating a pro-cancer role of SphK2 in the development of NAFLD-HCC (Suppl Fig. 7). Knockout of Sphk2 suppressed HFFHSD-induced HCC in mice, associated with inhibition of hepatic cell proliferation in a tumor-suppressive microenvironment. Mechanistically, Sphk2 deficiency resulted in downregulation of CERT, leading to a reduced ratio of SM/ceramide, which is unfavourable for HCC cell proliferation. Restoration of CERT expression substantially improved hepatic cell proliferation in Sphk2 deficient cells. Our findings demonstrate the Sphk2/CERT axis as a novel therapeutic target for NAFLD-HCC, although the intricate role of these coupled lipid regulators in different cancer contexts warrants further investigation.

MATERIALS AND METHODS

Animals

WT and Sphk2-KO mice on a C57BL/6J background were used according to protocols (#2019-033) approved by Research Ethics and Governance Office, Royal Prince Alfred Hospital, Sydney, Australia. Sphk2-KO mice were obtained from Dr Richard Proia, National Institutes of Health, USA [67]. Mice were housed in a temperature-controlled, pathogen-free environment on a 12-hour light/dark cycle, and allowed food and water ad libitum. No statistical methods were used to predetermine the sample size. The sample size was estimated based on similar published studies indicating an up to 68.8% incidence of HCC tumors after HFD feeding [32–35]. We adopted a sample size of n = 14 per group, which was sufficient to achieve statistically significant differences. Male mice aged 8 weeks with matched body weights were fed with an HFFHSD, using the recipe detailed in [68] with no cholesterol, for 46 weeks. Liver tissue and plasma were collected after 16 h starvation at the endpoint of the project. Levels of plasma NEFA, TC, TG, and ALT activity were analyzed using colorimetric assays (NEFA, TC, and TG kits from Fujifilm Wako Diagnostics, Osaka, Japan; ALT kit from Sigma-Aldrich, St. Louis, USA), as described previously [69].

Histological and immunohistochemical staining

The histology of mouse liver tissues was examined by H&E staining. The grading of NAS, encompassing steatosis, ballooning, and inflammation scores, was determined by three experienced researchers who were blinded to the experimental groups based on H&E staining following the scoring system established by Liang et al. [70]. Liver fibrosis was examined by Picro Sirius Red (PSR) staining (Sigma-Aldrich, St. Louis, USA). Immunohistochemical staining of K67 was performed with K67 antibody (Abcam Fab15580, Cambridge, UK). Images were taken using a Nikon NIE microscope and quantified using ImageJ software (FUI version 1.52).

Cell culture

The Huh7 hepatic cell line was obtained from and authenticated (Dec 2021) by CellBank Australia. Cells were tested mycoplasma-free by MycoAlert Detection Kit (Lonza Bioscience, Basel, Switzerland). Cells were maintained in Eagle’s minimal essential medium (DMEM) supplemented with 10% v/v fetal calf serum and 100 U/ml penicillin/streptomycin at 37 °C in a humidiﬁed incubator. Flag-tagged human CERT plasmid in pCDNA3.1/Zeo(+) vector was obtained from Genscript (Galaxis West Lobby, Royal Prince Alfred Hospital, Sydney, Australia. Materials and methods.

Walter and Miller (2021) Oncogenesis (2022) 11:67
Singapore). Plasmid transfection was conducted using lipofectamine LTX PLUS reagent (Thermo Fisher, Waltham, USA). Short-hairpin RNAs (shRNAs) targeting SphK2 (#A, TRCN0000036973 and #B, TRCN0000359275) were constructed in pLKO.1 lentiviral vector (Sigma-Aldrich, St. Louis, USA). The lentivirus was generated in HEK293T cells using plasmids gifted from Dr. Didier Trono through Addgene, including pMD2.G, pMDLg/pRRE and pRSV-Rev [71]. Lentiviral transduction was carried out as described previously [28]. To simulate a high-fat environment, we treated cells with a combination of bovine serum albumin-coupled palmitate (200 μM, Sigma-Aldrich, St. Louis, USA) and oleate (400 μM, Sigma-Aldrich, St. Louis, USA). C6-ceramide and fumonisin B1 were supplied by Avanti Polar Lipids (Alabaster, USA) and Cayman Chemical (Michigan, USA), respectively.

**Cell viability assay**

Cell viability was examined by 3-(4,5-dimethyl-thiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay (Promega, Madison, USA). The luminescence was determined at 490 nm on a TECAN Infinite M1000Pro plate reader.

**Colonial formation assay**

Huh7 cells were seeded at 400 (Fig. 3B) or 800 (Fig. 6C) cells/well in 6-well plates. Cells were treated with FFA combination for 10 days. Colonies were fixed with 4% cold paraformaldehyde, followed by crystal violet (0.5% w/v, Sigma-Aldrich, St. Louis, USA) staining [72]. Images were captured using a ChemiDoc™ Touch Imaging System (Bio-Rad Laboratories, Hercules, USA) and quantified using ImageJ software (FIJI version 1.52).

**Flow cytometry**

Cell cycle was examined in Huh7 cells fixed with 70% cold ethanol at 4°C overnight. The fixed cells were then incubated with FxCycle™/PR/RNase Staining Solution (Thermo Fisher, Waltham, USA) for 30 min at room temperature and analyzed using BD LSRII (BD Biosciences, Franklin Lakes, USA) [72]. G2/M phase was determined using FlowJo version 10 (BD Biosciences, Franklin Lakes, USA) in Waston (Pragmatic) mode.

**Confocal microscopy**

Intracellular FC was probed by the transfection of mCherry-D4H [73, 74], while the nuclei were counterstained with ProLong Glass Antifade Mountant with NucBlue Stain. The confocal microscopy was performed on a Q Exactive HF-X spectrometer with ion mobility using high and low fragmentation energy, supplemented with 0.01% formic acid and 200 pg/µL Leu-enkephalin, and quantified using X.T. Liu et al.

**lipid Kim Pham et al.**

Lipids were extracted from mouse liver tissues or Huh7 cells in 1 mL methanol containing a cohort of internal lipid standards (Avanti polar Lipids, Alabaster, USA). The liver tissues isolated from the first 8 animals of each genotype were analysed. Hepatic levels of TG, CE, and phospholipids were quantified using targeted lipidomic profiling on a Q Exactive HF-X mass spectrometer, following lipid separation on a Waters Acquity C18 UPLC column [53]. LipidSearch software was used for lipid annotation, chromatogram alignment and peak integration [75]. In contrast, FFA's, DG, FC, and sphingolipids were determined by targeted lipidomics on a TSQ Altis triple quadrupole mass spectrometer, following lipid separation on an Agilent Eclipse Plus C8 column [28, 53]. Peaks were integrated using Xcalibur (Thermo Fisher, Waltham, USA) [28].

**Western blotting**

Proteins were extracted from liver tissue (isolated from the first 8 animals of each genotype) and Huh7 cells. Immunoblotting was conducted with the following antibodies: SphK1 (#12071), SphK2 (#32346, human-specific, used for Huh7 cells), FLAG (#14793), p-p65 (#3033), t-p65 (#4764) and GAPDH (#5174) from Cell Signaling Technology (Dunsers, USA); nSMase 2 (#ab131330) from Abcam (Cambridge, UK); SphK2 (#17096-1-AP, used for mouse liver tissues), CERT (#15191-1-AP), SM1 (#19050-1-AP) and aSMase (#14609-1-AP) from Proteintechn (Rosemont, USA). Chemiluminescence was detected with a BIORAD ChemiDoc TOUCH imaging system.

**Quantitative RT-PCR**

RNA extraction and reverse transcription were performed, as previously described [75]. RT-PCR was carried out on a Roche Lightcycler 480 machine using SensisFast™ SYBR Lo-ROX Kit (Bioline, London, UK). Primer sets used for PCR were human/mouse CERT1/CERT F- CGATGGTCTCCGTCCAAAT, R- CCATCCCTGGTTTCACATT (designed using Primer-BLAST, National Center for Biotechnology Information, USA); mouse Gapdh F-CCGTGGAGAACTCTCC CAAG, R-TCATGTCTACACAGGAAATG [77]; human GAPDH F-CCGAGTCACAGGTAGGGTC, R-CCATGGTGGAATCATATG [78].

**Gene correlation analysis**

mRNA expression data of SHP2 and CERT1 were extracted from the Liver Hepatocellular Carcinoma (LHIC) dataset generated by TCGA via https://portal.gdc.cancer.gov. We assessed 158 primary liver cancer cases that were overweight/obese subjects (BMI > 25). After determining both variables were not normally distributed by the Shapiro-Wilk test, SHP2 and CERT1 data (transcripts per million) were log-transformed (natural log), followed by Pearson's correlation analyses using Prism 9 (GraphPad, version 9).

**Statistics**

Comparisons between two groups were analyzed by unpaired two-tailed t-tests, multiple comparisons were analyzed by one-way ANOVA with Tukey tests, and variance between groups were analyzed by F test, using GraphPad Prism version 9. The exact sample size and number of replicates (n) are indicated in the figure legends. Differences at values of p < 0.05 were considered significant.

**DATA AVAILABILITY**

All data supporting the findings of this study will be made available by the authors without undue reservation.

**REFERENCES**

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
2. Llovet JM, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7:6.
3. Marrero JA, Kulik LM, Sriniv CB, Zhu AX, Finn RS, Abbacess MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723–50.
4. Tan DJH, Ng CH, Lin SY, Pan HX, Tay P, Lim WH, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;33:521–30.
5. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537–64.
6. Foerster F, Gairing SJ, Muller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol. 2022;76:446–57.
7. Ando Y, Jou JH. Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis. (Hoboken). 2021;17:23–8.

Oncogenesis (2022)11:67
11. Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, DeSantis D, Hisao G, et al. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet. 2009;18:2975–88.

12. Coia H, Ma N, Hou Y, Dyba MD, Fu Y, Cruz MI, et al. Prevention of lipid peroxidation-derived cyclic DNA adduct and mutation in high-fat diet-induced hepatocarcinogenesis by the epoxide hydrolase thymoquinone. Cancer Prev Res (Philoc). 2018;11:6565–76.

13. Tafesse FG, von Felden J, Goea CV, Tuncgoz S, Villanueva A. Tumor evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:139–52.

14. Neubauer HA, Pham DH, Zebol JR, Moretti PA, Peterson AL, Leclercq TM, et al. An oncogenic role for sphingosine kinase 2. Oncotarget 2016;7:64886–99.

15. Semova I, Bidding SB. Triglycerides in nonalcoholic fatty liver disease: guilty until proven innocent. Trends Pharm Sci. 2021;42:183–90.

16. Liu D, Wong CC, Fu L, Chen H, Zhao L, Li C, et al. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med. 2018;10:eaaq9840.

17. Enriquez-Cortina C, Bello-Monroy O, Rosales-Cruz P, Souza V, Miranda RU, Toledo-Pereyra R, et al. Cholesterol overload in the liver aggravates oxidative stress-mediated DNA damage and accelerates hepatocarcinogenesis. Oncotarget 2017;8:104136–48.

18. Ribas V, de la Rosa LC, Robles D, Nunez S, Segales P, Insauti-Urria N, et al. Dietary and genetic cholesterol loading rather than steatosis promotes liver tumorigenesis and NASH-driven HCC. Cancers (Basel). 2021;13.

19. Smith B, Land H. Anticancer activity of the cholesterol exporter ABCA1 gene. Cell Rep. 2012;5:580–90.

20. Montero J, Morales A, Llacuna L, Lluis JM, Terrones O, Basanez G, et al. Mitochondrial cholesterol contributes to chemoresistance in hepatocellular carcinoma. Cancer Res. 2008;68:5246–56.

21. Li X, Teoh N, Xu L, Pok S, Li X, Chu ESH, et al. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling. Nat Commun. 2018;9:4490.

22. Nagahashi M, Takabe K, Liu R, Peng K, Wang X, Yang W, et al. Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. Hepatology 2015;61:1216–26.

23. van der Windt DJ, Sud V, Zhang H, Varley PR, Gossiawm J, Yazdani HO, et al. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology 2018;68:1347–60.

24. Liu J, Han L, Zhu L, Yu Y. Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats. Lipids Health Dis. 2016;15:27.

25. Wu H, Ng R, Chen X, Steer CJ, Song G. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBPI-p53-Srebp1c pathway. Gut. 2016;65:1850–60.

26. Donnelly KL, Smith CJ, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non-alcoholic fatty liver disease. J Clin Invest. 2005;115:1343–51.

27. Ito K, Anada Y, Tani M, Ikeda M, Sano T, Kihara A, et al. Lack of sphingolipase 1-phosphate-degrading enzymes in erythrocytes. Biochim Biophys Acta. 2004;1700:177–82.

28. Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitors. Curr Pharmacol Rep. 2019;5:273–82.

29. Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumor evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:139–52.

30. Granero F, Revert F, Revert-Ros F, Lainez S, Martinez-Martinez P, Saus J. A human-specific TFNC-responsive promoter for Goodpasture antigen-binding protein. FEBS J. 2005;272:398–405.

31. Tajima K, Nakamura H, Shirakawa J, Togashi Y, Orime K, Sato K, et al. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice. Am J Pathol. 2009;175:355–64.
1. Qi Y, Chen J, Lay A, Don A, Vadas M, Xia P. Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic beta-cell death in diet-induced obese mice. FASEB J. 2013;27:4294–304.
2. Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R, et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS ONE. 2014;9:e115922.
3. Muzzigoli K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol. 2005;25:11113–21.
4. Henderson JM, Polak N, Chen J, Roediger B, Weninger W, Kench JG, et al. Multiple liver insults synergize to accelerate experimental hepatocellular carcinoma. Sci Rep. 2018;8:10283.
5. Wang M, Zheng S, Li X, Ding Y, Zhang M, Lin L; et al. Integrated analysis of IncRNA-miRNA-mRNA ceRNA network, identified IncRNA EPB1L4A-A51 as a potential biomarker in non-small cell lung cancer. Front Genet. 2020;11:511676.
6. Trapika I, Liu XT, Chung LH, Lai F, Xie C, Zhao Y, et al. Ceramide regulates anti-tumor mechanisms of erianin in androgen-sensitive and castration-resistant prostate cancers. Front Oncol. 2021;11:738078.
7. Maekawa M, Fairn GD. Complementary probes reveal that phosphatidylserine is required for the proper transbilayer distribution of cholesterol. J Cell Sci. 2015;128:1422–33.
8. Wang H, Ma Q, Qi Y, Dong J, Du X, Rae J, et al. ORP2 delivers cholesterol to the plasma membrane in exchange for phosphorylinozitol 4, 5-bisphosphate (P(1,4,5)P2). Mol. Cell. 2019;73:458–73.e7.
9. Qi Y, Kapterian AS, Tu D, Ma Q, Fei W, Zhang Y, et al. CDP-diacylglycerol synthases regulate the growth of lipid droplets and adipocyte development. J Lipid Res. 2016;57:767–80.
10. Zhou L, Luo M, Chen X, Yin Y, Xiong X, Wang R, et al. Ion mobility collision cross-section atlas for known and unknown metabolite annotation in untargeted metabolomics. Nat Commun. 2020;11:4334.
11. Tran C, Heng B, Teo JD, Humphrey SJ, Qi Y, Couttas TA, et al. Sphingosine 1-phosphate but not Fingolimod protects neurons against excitotoxic cell death by inducing neurotrophic gene expression in astrocytes. J Neurochem. 2020;153:173–88.
12. Dai L, Qi Y, Chen J, Kaczorowski D, Di W, Wang W, et al. Sphingosine kinase (SphK) 1 and SphK2 play equivalent roles in mediating insulin’s mitogenic action. Mol Endocrinol. 2014;28:197–207.

ACKNOWLEDGEMENTS
We acknowledge Dr. Richard L. Proia (NIH) for the kind gift of global Sphk2-KO mice and Dr. Gregory D Fairn for sharing the FC probe mCherry-D4H. We also gratefully acknowledge subsidized access to the Sydney Mass Spectrometry and the Sydney Microscopy & Microanalysis core facilities at The University of Sydney.

AUTHOR CONTRIBUTIONS
YQ, SZ, and ASD conceived and coordinated the project. MDG and GM contributed to project supervision and design. XTL, DL, JC, and JDT performed animal work and pathology. LHC, YQ, ASD, and YH conducted lipidomics. LHC, YQ, and TAC performed mass spectrometry imaging. XTL, LHC, and CT performed cell biology experiments. FG and KL collected human HCC samples. JYL and YQ conducted gene correlation analysis. YQ drafted the manuscript. All authors contributed to the interpretation of the data and have approved the contents of the manuscript.

FUNDING
This study was supported by National Health and Medical Research Council, Australia (NHMRC) Project Grant GNT1162545 (YQ), NHMRC Ideas Grant GNT2002660 (ASD and YQ), and Centenary Institute Future Leader Fellowship (YQ).

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41389-022-00444-0.
Correspondence and requests for materials should be addressed to Anthony S. Don, Shubiao Zhang or Yanfei Qi.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022